REGENERON PHARMACEUTICALS, INC. Quarterly Costs and Expenses in USD from Q1 2010 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Total costs of sales and operating expenses for the period.
Summary
Regeneron Pharmaceuticals, Inc. quarterly/annual Costs and Expenses history and growth rate from Q1 2010 to Q3 2024.
  • Regeneron Pharmaceuticals, Inc. Costs and Expenses for the quarter ending September 30, 2024 was $2.54B, a 12.9% increase year-over-year.
  • Regeneron Pharmaceuticals, Inc. Costs and Expenses for the twelve months ending September 30, 2024 was $9.87B, a 11.2% increase year-over-year.
  • Regeneron Pharmaceuticals, Inc. annual Costs and Expenses for 2023 was $9.07B, a 22% increase from 2022.
  • Regeneron Pharmaceuticals, Inc. annual Costs and Expenses for 2022 was $7.43B, a 4.34% increase from 2021.
  • Regeneron Pharmaceuticals, Inc. annual Costs and Expenses for 2021 was $7.12B, a 44.8% increase from 2020.
Costs and Expenses, Trailing 12 Months (USD)
Costs and Expenses, Quarterly (USD)
Costs and Expenses, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $9.87B $2.54B +$290M +12.9% Jul 1, 2024 Sep 30, 2024 10-Q 2024-10-31
Q2 2024 $9.58B $2.48B +$336M +15.7% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-01
Q1 2024 $9.25B $2.39B +$178M +8.04% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-02
Q4 2023 $9.07B $2.46B +$194M +8.55% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-05
Q3 2023 $8.88B $2.25B +$539M +31.5% Jul 1, 2023 Sep 30, 2023 10-Q 2024-10-31
Q2 2023 $8.34B $2.14B +$394M +22.6% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-01
Q1 2023 $7.94B $2.22B +$509M +29.8% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-02
Q4 2022 $7.43B $2.27B -$44.4M -1.92% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-05
Q3 2022 $7.48B $1.71B +$107M +6.66% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-02
Q2 2022 $7.37B $1.75B -$44M -2.46% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-03
Q1 2022 $7.42B $1.71B +$291M +20.5% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 $7.12B $2.31B +$1.06B +84.1% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-05
Q3 2021 $6.07B $1.61B +$365M +29.4% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 $5.7B $1.79B +$496M +38.3% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-03
Q1 2021 $5.21B $1.42B +$288M +25.5% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-04
Q4 2020 $4.92B $1.26B +$68.1M +5.73% Oct 1, 2020 Dec 31, 2020 10-K 2021-02-08
Q3 2020 $4.85B $1.24B +$236M +23.4% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 $4.62B $1.3B +$33.4M +2.65% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 $4.58B $1.13B +$236M +26.4% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 $4.35B $1.19B -$21.9M -1.81% Oct 1, 2019 Dec 31, 2019 10-K 2021-02-08
Q3 2019 $4.37B $1.01B -$31.4M -3.03% Jul 1, 2019 Sep 30, 2019 10-K 2021-02-08
Q2 2019 $4.4B $1.26B +$276M +28% Apr 1, 2019 Jun 30, 2019 10-K 2021-02-08
Q1 2019 $4.12B $893M -$51.7M -5.48% Jan 1, 2019 Mar 31, 2019 10-K 2021-02-08
Q4 2018 $4.18B $1.21B +$166M +15.9% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-07
Q3 2018 $4.01B $1.04B +$95.9M +10.2% Jul 1, 2018 Sep 30, 2018 10-K 2020-02-07
Q2 2018 $3.91B $986M +$66M +7.18% Apr 1, 2018 Jun 30, 2018 10-K 2020-02-07
Q1 2018 $3.85B $944M +$55.9M +6.29% Jan 1, 2018 Mar 31, 2018 10-K 2020-02-07
Q4 2017 $3.79B $1.04B +$164M +18.6% Oct 1, 2017 Dec 31, 2017 10-K 2020-02-07
Q3 2017 $3.63B $941M +$83.4M +9.73% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-06
Q2 2017 $3.55B $920M -$1.2M -0.13% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-02
Q1 2017 $3.55B $888M +$16.9M +1.94% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-03
Q4 2016 $3.53B $880M +$12.8M +1.48% Oct 1, 2016 Dec 31, 2016 10-K 2019-02-07
Q3 2016 $3.52B $857M +$112M +15.1% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-08
Q2 2016 $3.4B $921M +$267M +40.9% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-03
Q1 2016 $3.14B $872M +$285M +48.7% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-04
Q4 2015 $2.85B $867M +$280M +47.8% Oct 1, 2015 Dec 31, 2015 10-K 2018-02-08
Q3 2015 $2.57B $745M +$208M +38.7% Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-04
Q2 2015 $2.36B $654M +$216M +49.4% Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-04
Q1 2015 $2.15B $586M +$152M +35% Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-05
Q4 2014 $2B $587M +$171M +41.2% Oct 1, 2014 Dec 31, 2014 10-Q 2015-11-04
Q3 2014 $1.82B $537M +$177M +49.2% Jul 1, 2014 Sep 30, 2014 10-Q 2015-11-04
Q2 2014 $1.65B $438M +$138M +46.1% Apr 1, 2014 Jun 30, 2014 10-Q 2015-08-04
Q1 2014 $1.51B $434M +$148M +51.5% Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-07
Q4 2013 $1.36B $415M +$146M +54.4% Oct 1, 2013 Dec 31, 2013 10-K 2016-02-11
Q3 2013 $1.22B $360M +$135M +59.9% Jul 1, 2013 Sep 30, 2013 10-Q 2014-11-04
Q2 2013 $1.08B $300M +$82.6M +38.1% Apr 1, 2013 Jun 30, 2013 10-Q 2014-08-05
Q1 2013 $998M $287M +$77M +36.8% Jan 1, 2013 Mar 31, 2013 10-Q 2014-05-08
Q4 2012 $921M $269M +$101M +59.7% Oct 1, 2012 Dec 31, 2012 10-K 2015-02-12
Q3 2012 $820M $225M +$64M +39.7% Jul 1, 2012 Sep 30, 2012 10-Q 2013-11-05
Q2 2012 $756M $217M +$48.8M +29% Apr 1, 2012 Jun 30, 2012 10-Q 2013-08-06
Q1 2012 $707M $210M +$56.4M +36.8% Jan 1, 2012 Mar 31, 2012 10-Q 2013-05-03
Q4 2011 $651M $168M +$21.9M +15% Oct 1, 2011 Dec 31, 2011 10-K 2014-02-13
Q3 2011 $629M $161M +$23.2M +16.8% Jul 1, 2011 Sep 30, 2011 10-Q 2012-10-24
Q2 2011 $606M $168M +$28.5M +20.4% Apr 1, 2011 Jun 30, 2011 10-Q 2012-07-25
Q1 2011 $577M $153M +$20.8M +15.7% Jan 1, 2011 Mar 31, 2011 10-Q 2012-04-26
Q4 2010 $557M $146M Oct 1, 2010 Dec 31, 2010 10-K 2013-02-15
Q3 2010 $138M Jul 1, 2010 Sep 30, 2010 10-Q 2011-10-27
Q2 2010 $140M Apr 1, 2010 Jun 30, 2010 10-Q 2011-07-28
Q1 2010 $132M Jan 1, 2010 Mar 31, 2010 10-Q 2011-05-03
* An asterisk sign (*) next to the value indicates that the value is likely invalid.